C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2026)

C4 Therapeutics has reported Long-Term Investments for 6 years, with the latest figure at $32.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 66.17% year-over-year to $32.6 million; the trailing twelve-month figure through Mar 2026 stood at $32.6 million (up 66.17% YoY), and the FY2025 full-year result was $48.6 million, up 117.2% from the prior year.
• Long-Term Investments for Q1 2026 stood at $32.6 million, down from $48.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $130.5 million in Q1 2022, with the low at $7.9 million in Q3 2025.
• Average Long-Term Investments over 5 years is $40.4 million, with a median of $31.6 million recorded in 2024.
• Year-over-year, Long-Term Investments surged 301.53% in 2022 and tumbled 78.44% in 2023.
• Tracing CCCC's Long-Term Investments over 5 years: stood at $61.0 million in 2022, then tumbled by 54.06% to $28.0 million in 2023, then declined by 20.17% to $22.4 million in 2024, then jumped by 117.2% to $48.6 million in 2025, then tumbled by 32.87% to $32.6 million in 2026.
• The last three Long-Term Investments figures came in at $32.6 million (Q1 2026), $48.6 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.

Peer Comparison